Comparative Pharmacology
Head-to-head clinical analysis: KRAZATI versus LUMAKRAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KRAZATI versus LUMAKRAS.
KRAZATI vs LUMAKRAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KRAZATI (adagrasib) is a selective, covalent inhibitor of KRAS G12C. It irreversibly binds to the cysteine residue in the KRAS G12C mutant protein, locking it in an inactive GDP-bound state, thereby inhibiting downstream signaling pathways (e.g., MAPK) and reducing tumor cell proliferation.
KRAS G12C inhibitor that irreversibly and selectively binds to the cysteine-12 residue in the switch-II pocket, locking KRAS in an inactive GDP-bound state and inhibiting downstream signaling.
600 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after dose).
960 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after dose).
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours, supporting once-daily dosing.
Terminal elimination half-life of 11 hours (range 5–15 hours), supporting twice-daily dosing.
Primarily excreted via feces (80% as unchanged drug), with renal excretion accounting for <1% of the dose.
Primarily hepatic metabolism; 88% in feces (53% as unchanged drug), 2% in urine (as metabolites).
Category C
Category C
KRAS Inhibitor
KRAS Inhibitor